4.4 Article Proceedings Paper

CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer

Journal

CELLS TISSUES ORGANS
Volume 185, Issue 1-3, Pages 95-99

Publisher

KARGER
DOI: 10.1159/000101308

Keywords

epithelial-mesenchymal transition; CCN; CCN6; WISP3; WISP; breast cancer; inflammatory breast cancer

Funding

  1. NATIONAL CANCER INSTITUTE [R01CA077612, K08CA090876, R01CA107469] Funding Source: NIH RePORTER
  2. NCI NIH HHS [K08 CA090876, R01 CA107469, R01 CA77612] Funding Source: Medline

Ask authors/readers for more resources

CCN6 (WISP3) is a cysteine-rich secreted protein that belongs to the CCN (Cyr61, CTGF, Nov) family of genes. We found that CCN6 mRNA is reduced in 80% of cases of the most lethal form of locally advanced breast cancer, inflammatory breast cancer. CCN6 contains four highly conserved motifs with sequence similarities to insulin-like growth factor binding proteins, von Willebrand type C, thrombospondin 1, and a carboxyl-terminal domain putatively involved in dimerization. CCN6 has tumor growth-, proliferation-, and invasion-inhibitory functions in breast cancer. Recently, by using a small infering RNA to downregulate CCN6 in immortalized human mammary epithelial cells, CCN6 was found to be essential to induce the process of epithelial-mesenchymal transition (EMT) with repression of E-cadherin gene expression and induction of a protein expression program characteristic of EMT. This review will focus on the current knowledge regarding the function of CCN6 in breast cancer with special emphasis on the emerging role of CCN6 as a regulator of the epithelial phenotype and E-cadherin expression in the breast. Copyright (c) 2007 S. Karger AG, Basel.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available